193 related articles for article (PubMed ID: 29248718)
1. Proteomic Characterization of Prostate Cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases.
Müller AK; Föll M; Heckelmann B; Kiefer S; Werner M; Schilling O; Biniossek ML; Jilg CA; Drendel V
Neoplasia; 2018 Feb; 20(2):140-151. PubMed ID: 29248718
[TBL] [Abstract][Full Text] [Related]
2. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
3. An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.
Zhang AY; Chiam K; Haupt Y; Fox S; Birch S; Tilley W; Butler LM; Knudsen K; Comstock C; Rasiah K; Grogan J; Mahon KL; Bianco-Miotto T; Ricciardelli C; Böhm M; Henshall S; Delprado W; Stricker P; Horvath LG; Kench JG
Int J Cancer; 2019 Mar; 144(5):1151-1159. PubMed ID: 30288742
[TBL] [Abstract][Full Text] [Related]
4. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
5. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in lymph node-positive prostate cancer.
Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
[TBL] [Abstract][Full Text] [Related]
7. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
Becker F; Joerg V; Hupe MC; Roth D; Krupar R; Lubczyk V; Kuefer R; Sailer V; Duensing S; Kirfel J; Merseburger AS; Brägelmann J; Perner S; Offermann A
Int J Cancer; 2020 Jan; 146(2):577-588. PubMed ID: 31271443
[TBL] [Abstract][Full Text] [Related]
8. The Value of
Su HC; Zhu Y; Hu SL; Liu C; Lin GW; Dai B; Zhang YJ; Ye DW
Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
[TBL] [Abstract][Full Text] [Related]
9. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
10. See the unseen: Mesorectal lymph node metastases in prostate cancer.
Hijazi S; Meller B; Leitsmann C; Strauss A; Ritter C; Lotz J; Meller J; Trojan L; Sahlmann CO
Prostate; 2016 Jun; 76(8):776-80. PubMed ID: 26880517
[TBL] [Abstract][Full Text] [Related]
11. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
12. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression and CD8
Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
[TBL] [Abstract][Full Text] [Related]
14. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent.
Tilki D; Reich O; Graser A; Hacker M; Silchinger J; Becker AJ; Khoder W; Bartenstein P; Stief CG; Loidl W; Seitz M
Eur Urol; 2013 May; 63(5):792-6. PubMed ID: 22902037
[TBL] [Abstract][Full Text] [Related]
15. CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.
Bauman TM; Ewald JA; Huang W; Ricke WA
BMC Cancer; 2015 Jul; 15():549. PubMed ID: 26209327
[TBL] [Abstract][Full Text] [Related]
16. Pelvic lymph node dissection in prostate cancer.
Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
[TBL] [Abstract][Full Text] [Related]
17. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281
[TBL] [Abstract][Full Text] [Related]
19. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
[TBL] [Abstract][Full Text] [Related]
20. Proteomic characteristics reveal the signatures and the risks of T1 colorectal cancer metastasis to lymph nodes.
Zhuang A; Zhuang A; Chen Y; Qin Z; Zhu D; Ren L; Wei Y; Zhou P; Yue X; He F; Xu J; Ding C
Elife; 2023 May; 12():. PubMed ID: 37158593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
